Bringing the Oncology Community Together

Dr. Weber Explores Nivolumab in Advanced Melanoma

Jeffrey S. Weber, MD, PhD
Published Online: Friday, June 21, 2013
Jeffrey S. Weber, MD, PhD, the director of the Donald A. Adam Comprehensive Melanoma Research Center at the Moffitt Cancer Center and Research Institute in Tampa, FL, describes a single institution phase I/II trial exploring the anti-PD-1 antibody nivolumab in combination with a peptide vaccine for patients with unresectable melanoma.

The trial divided 90 patients with unresectable melanoma who were naïve or refractory to ipilimumab into several cohorts to allow for individual analyses. Overall, Weber notes, response rates were similar between patients who were ipilimumab naive (28%) and those who were refractory (32%). Additionally, correlative immune assays were performed to examine possible biomarkers, such as the affect of PD-L1 positivity on response.

The examination of PD-L1 was undertaken to reproduce earlier work suggesting that PD-L1 was a predictive marker of response for nivolumab. Overall, an association between tumor PD-L1 and response was discovered; however, this association was not definitive. In general, Weber notes, patients who did not test positive for PD-L1 still responded to nivolumab.

Related Articles
Durable T-VEC Responses Fail to Prolong Survival in Updated Analysis
Talimogene laherparepvec significantly improved durable response rates but failed to extend overall survival in patients with advanced melanoma.
Pancoast Tumors of the Lung: Improved Results
Every patient with a pancoast tumor of the lung should be evaluated by a Pancoast-experienced thoracic surgeon (and neurosurgeon) before ruling out surgery, and before starting induction therapy.
Immunotherapy Biomarkers and Combinations Needed in CRPC: An Interview With Padmanee Sharma, MD, PhD
An interview with Padmanee Sharma, MD, PhD, on the evolving field of immunotherapy for patients with castration-resistant prostate cancer.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.